HRT trials that initiate estrogen-only therapy close to the menopause such as the Million Women Study in the UK [46] have not found an estrogen-induced decrease in breast cancer, raising the question for the above hypothesis—if estrogen is functioning to activate the DREAM pathway, then why is there a need for the five-year gap? Here, KCNIP3 is linked to breast cancer.